AU2022408097B2 - Methods of administering a modulator of hemoglobin - Google Patents

Methods of administering a modulator of hemoglobin

Info

Publication number
AU2022408097B2
AU2022408097B2 AU2022408097A AU2022408097A AU2022408097B2 AU 2022408097 B2 AU2022408097 B2 AU 2022408097B2 AU 2022408097 A AU2022408097 A AU 2022408097A AU 2022408097 A AU2022408097 A AU 2022408097A AU 2022408097 B2 AU2022408097 B2 AU 2022408097B2
Authority
AU
Australia
Prior art keywords
compound
dose
per day
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022408097A
Other languages
English (en)
Other versions
AU2022408097A1 (en
Inventor
Aline BARTH
Ken Duchin
Arthur Lo
Carla B. WASHINGTON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Blood Therapeutics Inc
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of AU2022408097A1 publication Critical patent/AU2022408097A1/en
Application granted granted Critical
Publication of AU2022408097B2 publication Critical patent/AU2022408097B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2022408097A 2021-12-10 2022-12-09 Methods of administering a modulator of hemoglobin Active AU2022408097B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163288377P 2021-12-10 2021-12-10
US63/288,377 2021-12-10
US202263421524P 2022-11-01 2022-11-01
US63/421,524 2022-11-01
US202263429376P 2022-12-01 2022-12-01
US63/429,376 2022-12-01
PCT/US2022/052411 WO2023107697A1 (en) 2021-12-10 2022-12-09 Methods of administering a modulator of hemoglobin

Publications (2)

Publication Number Publication Date
AU2022408097A1 AU2022408097A1 (en) 2024-05-30
AU2022408097B2 true AU2022408097B2 (en) 2026-03-12

Family

ID=85108880

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022408097A Active AU2022408097B2 (en) 2021-12-10 2022-12-09 Methods of administering a modulator of hemoglobin

Country Status (10)

Country Link
US (1) US20250041312A1 (https=)
EP (1) EP4444285A1 (https=)
JP (1) JP2024545496A (https=)
KR (1) KR20240116826A (https=)
AU (1) AU2022408097B2 (https=)
CA (1) CA3241881A1 (https=)
IL (1) IL312835A (https=)
MX (1) MX2024007064A (https=)
TW (1) TW202339732A (https=)
WO (1) WO2023107697A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4727555A1 (en) * 2023-06-13 2026-04-22 Global Blood Therapeutics, Inc. (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020106642A1 (en) * 2018-11-19 2020-05-28 Global Blood Therapeutics, Inc. 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
EP4337659A1 (en) * 2021-05-14 2024-03-20 Global Blood Therapeutics, Inc. Solid forms of a modulator of hemoglobin

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020106642A1 (en) * 2018-11-19 2020-05-28 Global Blood Therapeutics, Inc. 2-formyl-3-hydroxyphenyloxymethyl compounds capable of modulating hemoglobin

Also Published As

Publication number Publication date
TW202339732A (zh) 2023-10-16
KR20240116826A (ko) 2024-07-30
US20250041312A1 (en) 2025-02-06
CA3241881A1 (en) 2023-06-15
EP4444285A1 (en) 2024-10-16
MX2024007064A (es) 2024-06-20
AU2022408097A1 (en) 2024-05-30
IL312835A (en) 2024-07-01
JP2024545496A (ja) 2024-12-09
WO2023107697A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
TWI670060B (zh) 醛化合物及其醫藥組成物及用途
EP2275108A1 (en) Pharmaceutical preparation comprising dpp-iv inhibitor and other diabetes therapeutic agent in concomitant or combined form
US9441000B2 (en) Use of metallocene compounds for cancer treatment
AU2022408097B2 (en) Methods of administering a modulator of hemoglobin
EP3437644A1 (en) Medicine
US9504672B2 (en) Compositions and methods for treating or preventing pneumovirus infection and associated diseases
AU2022273787B2 (en) Solid forms of a modulator of hemoglobin
US20220185791A1 (en) Polymorphs of a cardiac troponin activator
AU2017215825B2 (en) Method for treating cancer patients with severe renal impairment
WO2011057220A2 (en) Compositions and methods for treating lymphoma
RU2855050C2 (ru) Способы введения модулятора гемоглобина
EP4727555A1 (en) (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease
US20140121220A1 (en) Crystals of phenylpyrrole derivative
CN118369092A (zh) 施用血红蛋白调节剂的方法
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
HK40107036A (zh) 施用血红蛋白调节剂的方法
CN115485265B (zh) 8-氯-n-(4-(三氟甲氧基)苯基)喹啉-2-胺的共晶和盐
WO2022033265A1 (zh) 治疗慢性肾病的方法和药物组合物
JP7289978B1 (ja) がん治療のための併用療法